EA200900470A1 - Dbait и ее применение - Google Patents

Dbait и ее применение

Info

Publication number
EA200900470A1
EA200900470A1 EA200900470A EA200900470A EA200900470A1 EA 200900470 A1 EA200900470 A1 EA 200900470A1 EA 200900470 A EA200900470 A EA 200900470A EA 200900470 A EA200900470 A EA 200900470A EA 200900470 A1 EA200900470 A1 EA 200900470A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dsb
repair
dna
pathway
methods
Prior art date
Application number
EA200900470A
Other languages
English (en)
Other versions
EA017418B1 (ru
Inventor
Мари Дютри
Дзиань-Шен Сунь
Original Assignee
Энститю Кюри
Сантр Насьональ Де Ля Решерш Сьентифик ( Снрс)
Мюзеум Насьональ Д'Истуар Натюрель
(Инсерм) Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Кюри, Сантр Насьональ Де Ля Решерш Сьентифик ( Снрс), Мюзеум Насьональ Д'Истуар Натюрель, (Инсерм) Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль filed Critical Энститю Кюри
Publication of EA200900470A1 publication Critical patent/EA200900470A1/ru
Publication of EA017418B1 publication Critical patent/EA017418B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к композициям и способам взаимодействия с репарацией двухцепочечных разрывов ДНК (DSB). Изобретение раскрывает новые двухцепочечные молекулы нуклеиновых кислот, действующие в качестве приманки и захватывающие голокомплекс ферментов, отвечающих за обнаружение DSB в ДНК, передачу сигнала о наличии DSB и/или пути репарации, в частности пути негомологичного соединения концов (NHEJ) при репарации DSB. Изобретение раскрывает применение таких молекул в качестве вспомогательных композиций для применения вместе с повреждающими ДНК способами лечения, особенно радиотерапией или химиотерапией, в комбинации с фармацевтически приемлемым носителем в эффективном количестве для внесения в ядро опухолевой клетки для временной нейтрализации их способности к репарации ДНК и запуска их гибели.
EA200900470A 2006-09-21 2007-09-20 Молекула нуклеиновой кислоты для воздействия на пути репарации двухцепочечных разрывов днк и ее применение EA017418B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/524,528 US7476729B2 (en) 2003-10-24 2006-09-21 Dbait and uses thereof
PCT/EP2007/059948 WO2008034866A2 (en) 2006-09-21 2007-09-20 Dbait and uses thereof

Publications (2)

Publication Number Publication Date
EA200900470A1 true EA200900470A1 (ru) 2009-08-28
EA017418B1 EA017418B1 (ru) 2012-12-28

Family

ID=39092538

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900470A EA017418B1 (ru) 2006-09-21 2007-09-20 Молекула нуклеиновой кислоты для воздействия на пути репарации двухцепочечных разрывов днк и ее применение

Country Status (15)

Country Link
US (2) US7476729B2 (ru)
EP (1) EP2064327B1 (ru)
JP (1) JP5415952B2 (ru)
CN (1) CN101528925B (ru)
CA (1) CA2662065C (ru)
CY (1) CY1119484T1 (ru)
DK (1) DK2064327T3 (ru)
EA (1) EA017418B1 (ru)
ES (1) ES2633652T3 (ru)
HU (1) HUE033978T2 (ru)
LT (1) LT2064327T (ru)
PL (1) PL2064327T3 (ru)
PT (1) PT2064327T (ru)
SI (1) SI2064327T1 (ru)
WO (1) WO2008034866A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EA023927B1 (ru) 2010-06-22 2016-07-29 Дна Терапьютикс ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ
AU2015202211B2 (en) * 2010-06-22 2016-09-01 Centre National De La Recherche Scientifique Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
KR101896567B1 (ko) * 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
JP6949859B2 (ja) * 2016-03-01 2021-10-13 オンクセオＯｎｘｅｏ Ｄｂａｉｔ分子の全身投与によるガンの処置
WO2017186882A1 (en) 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN107793468A (zh) * 2017-06-26 2018-03-13 上海悦良生物科技有限公司 一种检测dna损伤的方法
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US20220054524A1 (en) 2018-12-21 2022-02-24 Onxeo New conjugated nucleic acid molecules and their uses
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
EP4310182A1 (en) * 2022-07-19 2024-01-24 4basebio UK Ltd Protected dna and methods for the production thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501928A (ja) * 1992-07-02 1996-03-05 ハイブライドン インコーポレイテッド 治療剤としての自己安定化オリゴヌクレオチド
US6441158B1 (en) * 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
EP0978561A1 (en) 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
EP1487995A4 (en) 2002-02-13 2006-08-02 Medbridge Inc PROTEIN CARRIER SYSTEM FOR THERAPEUTIC OLIGONUCLEOTIDES
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1526177A1 (en) * 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality

Also Published As

Publication number Publication date
PT2064327T (pt) 2017-07-27
US7741308B2 (en) 2010-06-22
SI2064327T1 (sl) 2017-12-29
AU2007298990B2 (en) 2012-07-26
CN101528925B (zh) 2012-03-14
CY1119484T1 (el) 2018-03-07
AU2007298990A1 (en) 2008-03-27
CA2662065A1 (en) 2008-03-27
PL2064327T3 (pl) 2017-10-31
CA2662065C (en) 2015-11-24
EP2064327A2 (en) 2009-06-03
WO2008034866A3 (en) 2008-05-15
EA017418B1 (ru) 2012-12-28
DK2064327T3 (en) 2017-08-14
ES2633652T3 (es) 2017-09-22
HUE033978T2 (en) 2018-01-29
US20090156541A1 (en) 2009-06-18
WO2008034866A2 (en) 2008-03-27
JP5415952B2 (ja) 2014-02-12
JP2010504085A (ja) 2010-02-12
EP2064327B1 (en) 2017-04-26
US20070111961A1 (en) 2007-05-17
US7476729B2 (en) 2009-01-13
LT2064327T (lt) 2017-09-11
CN101528925A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
EA200900470A1 (ru) Dbait и ее применение
EA200900989A1 (ru) МОЛЕКУЛЫ Dbait И ИХ САМОСТОЯТЕЛЬНЫЕ ПРИМЕНЕНИЯ
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
MX2011007420A (es) Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
UA115983C2 (uk) Інгібітори днк-пк
WO2009018219A3 (en) Methods and compositions for modulating rad51 and homologous recombination
WO2019090148A3 (en) Compositions and methods related to therapeutic cell systems for tumor growth inhibition
TWI367886B (en) Proteasome inhibitors and methods of using the same
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
MX342128B (es) Compuestos farmaceuticos.
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
MX2012006936A (es) Evento de maiz dp-004114-3 y metodos para su deteccion.
NZ702050A (en) 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
WO2009149214A3 (en) Compositions and methods for enhancing cellular transport of biomolecules
MX2013002249A (es) Acidos nucleicos, composiciones y metodos para la escision de acidos nucleicos objetivos.
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
MX2008013397A (es) Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM